Articles producció científica> Medicina i Cirurgia

Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant

  • Dades identificatives

    Identificador: imarina:9297692
    Autors:
    Berenguer, JJarrin, IPerez-Latorre, LHontanon, VVivancos, MJNavarro, JTellez, MJGuardiola, JMIribarren, JARivero-Juarez, AMarquez, MArtero, AMorano, LSantos, IMoreno, JFarinas, MCGalindo, MJHernando, MAMontero, MCifuentes, CDomingo, PSanz, JDomingez, LFerrero, OLDe la Fuente, BRodriguez, CReus, SHernandez-Quero, JGaspar, GPerez-Martinez, LGarcia, CForce, LVeloso, SLosa, JEVilaro, JBernal, EArponen, SOrti, AJChocarro, ATeira, RAlonso, GSilvarino, RVegas, AGeijo, PBisbe, JEsteban, HGonzalez-Garcia, J
    Resum:
    Background. We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015.Methods. The study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility.Results. The reference population and the sample size were 38 904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy.Conclusions. Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.
  • Altres:

    Autor segons l'article: Berenguer, J; Jarrin, I; Perez-Latorre, L; Hontanon, V; Vivancos, MJ; Navarro, J; Tellez, MJ; Guardiola, JM; Iribarren, JA; Rivero-Juarez, A; Marquez, M; Artero, A; Morano, L; Santos, I; Moreno, J; Farinas, MC; Galindo, MJ; Hernando, MA; Montero, M; Cifuentes, C; Domingo, P; Sanz, J; Domingez, L; Ferrero, OL; De la Fuente, B; Rodriguez, C; Reus, S; Hernandez-Quero, J; Gaspar, G; Perez-Martinez, L; Garcia, C; Force, L; Veloso, S; Losa, JE; Vilaro, J; Bernal, E; Arponen, S; Orti, AJ; Chocarro, A; Teira, R; Alonso, G; Silvarino, R; Vegas, A; Geijo, P; Bisbe, J; Esteban, H; Gonzalez-Garcia, J
    Departament: Medicina i Cirurgia
    Autor/s de la URV: Veloso Esteban, Sergio
    Paraules clau: Update Therapy Spain/epidemiology Risk Outbreak Men Hiv-infected patients Hiv infection/epidemiology Hepatitis c/drug therapy/epidemiology Fibrosis Coinfection/epidemiology Care Acute hepatitis-c
    Resum: Background. We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015.Methods. The study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility.Results. The reference population and the sample size were 38 904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy.Conclusions. Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.
    Àrees temàtiques: Saúde coletiva Oncology Neurology (clinical) Microbiology Medicina ii Medicina i Infectious diseases Immunology Ciências biológicas i
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    Adreça de correu electrònic de l'autor: sergio.veloso@urv.cat
    Data d'alta del registre: 2024-09-07
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://academic.oup.com/ofid/article/5/1/ofx258/4804300?login=false
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referència a l'article segons font original: Open Forum Infectious Diseases. 5 (1):
    Referència de l'ítem segons les normes APA: Berenguer, J; Jarrin, I; Perez-Latorre, L; Hontanon, V; Vivancos, MJ; Navarro, J; Tellez, MJ; Guardiola, JM; Iribarren, JA; Rivero-Juarez, A; Marquez, (2018). Human Immunodeficiency Virus/Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant. Open Forum Infectious Diseases, 5(1), -. DOI: 10.1093/ofid/ofx258
    DOI de l'article: 10.1093/ofid/ofx258
    Entitat: Universitat Rovira i Virgili
    Any de publicació de la revista: 2018
    Tipus de publicació: Journal Publications
  • Paraules clau:

    Immunology,Infectious Diseases,Microbiology,Neurology (Clinical),Oncology
    Update
    Therapy
    Spain/epidemiology
    Risk
    Outbreak
    Men
    Hiv-infected patients
    Hiv infection/epidemiology
    Hepatitis c/drug therapy/epidemiology
    Fibrosis
    Coinfection/epidemiology
    Care
    Acute hepatitis-c
    Saúde coletiva
    Oncology
    Neurology (clinical)
    Microbiology
    Medicina ii
    Medicina i
    Infectious diseases
    Immunology
    Ciências biológicas i
  • Documents:

  • Cerca a google

    Search to google scholar